The NHLBI (National Heart, Lung and Blood Institute) T-cell depletion (TCD) randomized phase II-III multicenter trial was conducted to examine the impact of TCD of unrelated BM grafts on specific outcomes. The major findings of the study have been reported earlier; 1 however, an analysis of lymphocyte reconstitution for study patients has been recently performed and is presented in this report.
Patients received BM grafts from unrelated donors that were either infused unmanipulated, or were TCD using selective ex vivo depletion of ab þ T cells (abTCD) or a prescribed T-cell dose of 5 Â 10 5 cells/kg after counterflow centrifugal elutriation. Those randomized to receive unmanipulated grafts were conditioned with 1320-1375 cGy fractional TBI over 4 days and CY 120 mg/kg over 2 days. MTX (15 mg/m 2 on day 1 and 10 mg/m 2 on days þ 3, þ 6 and þ 11) and CsA were used as GVHD prophylaxis. Patients who received abTCD grafts received 1410 cGy fractionated TBI over 3 days and 100 mg/kg CY over 2 days. Patients who received elutriated grafts received 1320-1375 cGy fractional TBI over 4 days, CY 120 mg/kg over 2 days, and equine antithymocyte globulin over 2 days. All patients received post-BMT CsA sufficient to achieve trough levels of 200-400 ng/ml. Lymphocyte recovery was assessed at 1, 3, 6, 12, 18 and 24 months post-HSCT. To be included in this analysis, patients had to have survived at least 60 days and completed at least 2 of 3 initial post-BMT immunophenotyping assessments at the 30, 60 or 100-day post-BMT time point. Lymphocyte subsets were enumerated using dual platform flow cytometry with a whole blood lyse/wash procedure and staining with fluorochromeconjugated MoAbs to CD3, CD4, CD8, CD19, CD20, CD45, CD45RA, CD16, CD56, CD57, HLA-DR, TCR ab and TCR gd (BD Biosciences, San Jose, CA, USA). Data were tabulated and analyzed using SAS. Published normal ranges for lymphocyte subsets were used to determine time to complete lymphocyte recovery.
2,3 The Wilcoxon's nonparametric test was used to compare recovery of absolute cell counts between groups at each measurement period. A mixed model estimated the rate of change in cell counts for each subject and its slope estimate for each cell subset was then used as a variable to assess disease-free survival. The Cox proportional hazards model was used to examine associations between recovery of individual cell subsets and disease-free survival.
A total of 195 of 407 patients met the inclusion criteria for this analysis. These represented 100 of 206 (48.5%) recipients of unmanipulated grafts, 67 of 135 (49.6%) abTCD grafts and 28 of 66 (42.4%) elutriated grafts. Recipients of unmanipulated BMT grafts received a T-cell dose of 2.69 ± 2.09 Â 10 7 T cells/kg compared with 1.79 ± 3.00 Â 10 6 T cells/kg for recipients of abTCD grafts, and 5.29±4.0 Â 10 5 cells/kg for recipients of elutriated grafts. The T-cell dose differed significantly between the abTCD group and the elutriated group (P ¼ 0.02).
As shown in Figure 1 , the total absolute CD3, TCR ab, TCR gd, CD3 þ CD4 þ , CD3 þ CD8 þ recovery did not differ significantly beyond the first evaluation period for patients who received unmanipulated grafts and those who received TCD grafts. T-cell recovery trended slower after the 12-month evaluation period for all subsets other than gd T cells in recipients of abTCD grafts and was significant at 24 months for ab T-cell counts value (P ¼ 0.03). CD3 þ CD4 þ CD45RA naive T-cell recovery remained well below the average of 400/ml seen in healthy volunteers 3 for all time points. All groups showed prolonged B-cell count recovery (Figure 2a) .
Interestingly, natural killer (NK) cell absolute count was significantly higher in patients who received abTCD grafts through the first four evaluation periods than those who received unmanipulated grafts (Figure 2b ). NK recovery did not differ between patients who received elutriated grafts and patients who received unmanipulated grafts. The more robust recovery of NK cells has been observed in the setting of TCD 4 and is likely a result of homeostatic proliferation caused by enrichment of the graft for NK cells and the initial absence of T cells, which compete for similar growth factors. 4, 5 OS for this patient subset did not differ between recipients of unmanipulated grafts and recipients of TCD grafts as was shown for the total patient cohort. Cox proportional hazards analysis revealed that the slope (rate) of recovery of T cells (P ¼ 0.03) and CD19 þ B cells (P ¼ 0.04) was associated with improved disease-free survival independent of treatment group, findings that are consistent with published reports. [6] [7] [8] [9] [10] A limitation of this analysis, however, was that the small number of patients in this subset prevented a meaningful stratification of cell subset recovery by disease-specific or demographic parameters.
Earlier analysis of the total patient cohort revealed faster neutrophil recovery, decreased incidence of acute GVHD and reduced grade III-IV toxicities in the TCD group, however, TCD was associated with an increased risk of 
Horizontal lines designate lower normal values. The upper normal range was not exceeded and is omitted to allow more detail for the plots. Mean TCR-ab and CD3 þ CD4 þ CD45RA þ T-cell counts were consistently higher in the elutriated group but not so significant. Indeed, with the exception of ab T-cell numbers at 24 months post-BMT, no group showed statistically superior T-cell or T cell subset recovery at any time point. relapse in CML patients. 1 In this report, we have shown no differences in lymphocyte subset recovery beyond 60 days for patients in the therapy groups who received unmanipulated grafts and those who received a fixed lymphocyte dose after elutriation. Patients who received abTCD grafts showed significantly faster NK recovery but fewer abT cells at later time points. Taken together as an aggregate of the reports on this trial, we have shown that partial ex vivo TCD remains a reasonable platform for development of cell-based immunotherapies of cancer that permits timely lymphocyte recovery while minimizing the risk for acute GVHD.
